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Background: The increase in carbapenemase producing Enterobacteriaceae and Pseudomonas aeruginosa is a
significant threat to modern medicine. A rapid detection of carbapenemase production in Klebsiella pneumoniae
and Pseudomonas aeruginosa is of importance for the institution of correct antibiotic treatment and infection
control measures.
Results: Standardised inoculums of K. pneumoniae or P. aeruginosa were incubated at 37°C with ertapenem in 15
and 120 min followed by centrifugation. The supernatant was applied on a steel target plate, covered with HCCA
matrix and analysed using a MicroflexTM (Bruker Daltonics) in the mass range of 4–600 Da. The assay detected and
separated KPC from other carbapenemases in K. pneumoniae after only 15 min incubation. In P. aeruginosa,
however, only 8/14 isolates of VIM-producing P. aeruginosa were detected. None of the tested carbapenemase
negative isolates displayed a pattern of hydrolysis of ertapenem.
Conclusions: This assay allows for a very rapid detection and verification of KPC (45 min including the preparation
steps) and MBL production (150 min) in K. pneumoniae and can be performed using standard matrix. However, the
study revealed the need for optimization of the substrate/species combination in assays for the detection of
carbapenemases in P. aeruginosa using MALDI-TOF.
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The increase in carbapenemase-producing Enterobacte-
riaceae and Pseudomonas aeruginosa is a significant
threat to modern medicine [1]. As treatment options are
very limited, infection control measures are important to
contain carbapenemase-producing isolates in health care
settings. Rapid detection of carbapenemase-producers is
a decisive for adequate infection control measures to be
undertaken. The methods used so far for the detection
of carbapenemases have been phenotypic methods or
PCR [2,3] Recently, Matrix Assisted Laser Desorption
Ionization-Time Of Flight (MALDI-TOF) has been in-
troduced in clinical microbiology for species identifica-
tion and during the last two years a few studies have* Correspondence: christian.giske@karolinska.se
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article, unless otherwise stated.shown the proof of concept regarding the detection of
β-lactamases using this technology [4-6]. These studies
have either analyzed a small set of strains [4] or focused
on the detection of hydrolysis rather than the verifica-
tion of specific enzymes [5-8]. All studies have used dif-
ferent protocols and different sets of species/enzyme
combinations. In the present study we present a method
for the simultaneous detection and discrimination of
KPC from the metallo-β-lactamases (MBL) NDM and
VIM in Klebsiella pneumoniae and the possibility of
verification of VIM in Pseudomonas aeruginosa through
a time dependent hydrolysis assay and the addition of
specific inhibitors, APBA (3-aminophenylboronic acid)
and DPA (2.6-Pyridinecarboxylic acid).
Results
Stability of ertapenem
Ertapenem was stable after one week and six months
when stored at −20°C, but degraded after one weektral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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further analysis.
Klebsiella pneumoniae (n = 40)
All the KPC producing K. pneumoniae (n = 10) dis-
played the specific ertapenem hydrolysis peak pattern
after 15 min incubation (Figure 1, middle). As no
potassium was included in this assay only the so-
dium ions of hydrolysed ertapenem with the m/z ra-
tios of 450.5, 472.5, 494.5, 516.5 and 538.5 were
detected. The hydrolysis was inhibited by APBA
(Figure 1, bottom) as only the unhydrolysed forms of
ertapenem were detected with the m/z ratios of
476.5, 498.5, 520.5 and 542.5. The NDM- (n = 4) and
VIM-producing (n = 3) K. pneumoniae isolates did notFigure 1 Mass spectrum showing the non hydrolysed pattern of ertap
K. pneumoniae after 15 min (middle) and the effect of the supplement ofhydrolyse ertapenem in 15 minutes but hydrolysis was
observed after 120 minutes incubation (Figures 2 and
3). The hydrolysis of VIM- and NDM-enzymes was
fully inhibited by DPA (Figures 2 and 3). At these
concentrations the inhibition was 100% specific for
the respective enzyme. Ertapenem was not hydrolysed
by the ATCC 13882 or by the clinical isolates with
classical ESBL or acquired AmpC (n = 12) (Table 1).
All K. pneumoniae (n = 11) in the validation panel
with KPC, NDM, or VIM enzymes were correctly
assigned as KPC- or MBL-producers while none of
the isolates with OXA-48 enzyme (n = 3) displayed
hydrolysis after 2 h while all showed the pattern of
ertapenem hydrolysis after 24 h. A summary of the
results is presented in Table 1.enem (top), the full hydrolysis of ertapenem of a KPC producing
APBA inhibiting the KPC mediated hydrolysis of ertapenem (bottom).
Figure 2 Mass spectrum showing the non hydrolysed pattern of ertapenem (top), The non hydrolysed pattern of ertapenem after
15 min incubation together with NDM producing K. pneumoniae (middle top), the full hydrolysis of ertapenem of a NDM-producing
K. pneumoniae after 120 min (middle bottom) and the effect of the supplement of DPA inhibiting the NDM mediated hydrolysis of
ertapenem (bottom).
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Six out of elevenVIM producing P. aeruginosa, as well
as the IMP-14-producing isolate tested, hydrolysed erta-
penem after 120 minutes of incubation with the specific
ertapenem hydrolysis peak pattern. The hydrolysis was
fully inhibited in the presence of DPA in all cases. Erta-
penem was not hydrolysed by the non-carbapenemase
producing (no carbapenemase confirmed genetically or
phenotypically), carbapenem resistant, P. aeruginosa iso-
lates (n = 10). Of the 4 P. aeruginosa isolates included in
the validation panel (three VIM-1 and one VIM-2) were
correctly assigned as carbapenemase producers (both
VIM-1). The carbapenemase production was inhibited
by DPA both for VIM and IMP positive strains. Pro-
longed incubation (24 h) did not reveal any signs of hy-
drolysis in the strains tested negative after 120 min
incubation (one VIM-1 and one VIM-2). There was nolinkage between VIM-type and hydrolysis results. A
summary of the results is presented in Table 1.
Other species (Acinetobacter baumannii (n = 4), Escherichia
coli (n = 3)
None of the 4 Acinetobacter baumannii group isolates
(OXA-23 like (n = 2), OXA-24-like (n = 1) and OXA-58
like (n = 1)) included in the validation panel hydrolysed
ertapenem within 120 min incubation. All isolates, how-
ever, displayed the specific pattern of ertapenem hy-
drolysis after a prolonged incubation (24 h). The two
isolates of E. coli only producing a classical ESBL-
enzyme (two CTX-M-1 group and one CTX-M-1 group
plus CIT-group plasmid mediated AmpC) did not
hydrolyse ertapenem at any time point. The OXA-48
positive isolate of E. coli did not hydrolyse ertapenem
within 2 h, but prolonged incubation (24 h) revealed
Figure 3 Mass spectrum showing the non hydrolysed pattern of ertapenem (top), The non hydrolysed pattern of ertapenem after
15 min incubation together with VIM producing K. pneumoniae (middle top), the full hydrolysis of ertapenem of a VIM-producing
K. pneumoniae after 120 min (middle bottom) and the effect of the supplement of DPA inhibiting the VIM mediated hydrolysis of
ertapenem (bottom).
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Table 1.
Discussion
The drastic increase of isolates with the ability to produce
carbapenemases in Enterobacteriacae, Acinetobacter spp.
and P. aeruginosa rapidly challenges the treatment con-
cept of severely ill patients [1]. Whether the carbapenem
resistance is due to carbapenemase production or other
mechanisms is considered important for infection control
teams. Molecular methods are available for the verification
of the genes responsible for carbapenemase production
but have the limitation of not detecting new mechanisms
[9-11]. The phenotypic assays so far on the market have
problems with the time to result, isolates with low expres-
sion of the carbapenemase genes and that specific inhibi-
tors are not available for several enzymes [2]. The
introduction of MALDI-TOF for the detection of carbape-
nemases has seemed promising due to the versatile ap-
proach of the detection of hydrolysis and the seemingly
high sensitivity and specificity [5,7,8]. For the detection of
carbapenemases in Acinetobacter the use of imipenemhas been chosen [6,8] while for the detection of
carbapenemases in Enterobacteriaceae meropenem is
best validated but ertapenem has also been suggested
[5,7]. Most methods developed so far for this pur-
pose have only investigated very small collections, in
all 30 isolates, of P. aeruginosa [6,7,12] and only 10 isolates
with a VIM enzyme out of which 9 were detected. [6,12].
We included 25 isolates of P. aeruginosa out of which 14
carried a VIM enzyme and 1 an IMP-14-enzyme. Only 9
of these isolates could be detected (8 VIM and the only
tested IMP positive isolate) using this method based
on ertapenem. Both the VIM-type and absence of VIM-
production could be ruled out as possible explanations for
this. We therefore hypothesize that the non-hydrolysis of
ertapenem might be due to additional porin loss resulting
in a very low fraction of ertapenem (if any) to reach the
periplasmatic site of action of the VIM-enzyme [13]. This
finding is important as it shows that the local epidemio-
logical situation where both the mechanism and species of
interest may vary is important when choosing the right
method for the detection of carbapenemases. However,
when a carbapenemase was detected the use of inhibitor
Table 1 A synthesis of the results showing the basic data in relation to hydrolysis








Test panel K. pneumoniae KPC-2 (4) 4 - >32 4 - >32 2 - >32
KPC-3 (2) 10/10
KPC (4) 15 min
VIM-1 (3) 3/3 >32 32 - >32 8 - >32
120 min
NDM-1 (4) 4/4 >32 >32 >32
120 min
Classic ESBL (6) 0/6 na na 0.016 - 0.125
120 min
Acquired AmpC 6) 0/6 0.064 - 0.125 0.064 - 0.25 0.032 - 2
120 min
P. aeruginosa VIM-1 (2) >32 >32 >32
VIM-2 (6) 6/10
VIM (2) 120 min
IMP-14 (1)
Carba R 0/10 8 - >32 4 - >32 >32
(non-MBL) (10) 120 min
Validation panel A. baumannii OXA 23-like (n = 2) 4/4 >32 >32 >32
OXA 24-like (n = 1) 24 h
OXA 58-like (n = 1)
P. aeruginosa VIM-1 (3) 2/4 >32 >32 >32
VIM-2 (1) 120 min
K. pneumoniae OXA-48 (3) 3/3 24 h 4 - >32 4 - >32 1 - >32
KPC-2 (4) 4/4 15 min >32 >32 >32
VIM-1 (2) 2/2 120 min >32 >32 >32
NDM-1 (2) 2/2 >32 >32 >32
120 min
E. coli OXA-48 (1) 1/1 24 h 16 8 4
CTX-M-15 (n = 1) 0/2 0.125 - 0.25 0.25 - 0.5 0.064 - 0.125
CTX-M-15+ CIT (n = 1) 120 min and 24 h
*peaks m/z: 476.5, 498.5, 520.5 and 542.5 Da.
A synthesis of the results showing the species, resistance mechanism and MIC range in the test panel and validation panel in relation to the results in the
hydrolysis assay based on ertapenem.
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P. aeruginosa.
The rapid verification (45–150 min including the prep-
aration steps, incubation and MALDI-TOF analysis)
of carbapenemase production separating KPC isolates
from other carbapenemases is to our knowledge the
most rapid verification method of carbapenemases in
K. pneumoniae developed so far. As shown by others,
direct detection of carbapenemase production directly
from blood culture vials is possible [4] and could be of
great importance especially in hospitals with high inci-
dence of carbapenemase producing isolates, as the res-
cue treatment in these cases is associated with worsepatient outcome [14]. We did not have any IMP-
producing K. pneumoniae isolates available for this study
and the specificity for KPC of the 15 min hydrolysis might
thus be overrated. However the only IMP-producing P.
aeruginosa isolate did not hydrolyse ertapenem in 15 min
(data not shown).
The method presented here is not dependent on any
know-how in molecular biology and could be performed
in any laboratory having access to a MALDI-TOF with
open software allowing the manual analysis of mass spec-
tra in a m/z range far below the range of 2–20 kDa used
for species ID. We choose to build this assay on the hy-
drolysis of ertapenem as this hydrolysis is associated with
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easily visualized using the HCCA matrix used for species
ID and does not need the addition of SDS (as compared
to meropenem) [5]. The method accurately detection of
KPCs in K. pneumoniae and was not primarily developed
for detecting OXA-enzymes but these enzymes were intro-
duced in the “validation panel” to test the robustness of the
method in a clinical setting. The method failed to detect
OXA-enzymes in the validated time frame of 2 h. However
a prolonged incubation for 24 h displayed the hydrolysis
pattern in K. pneumoniae, Acinetobacter spp. and E.coli
while the controls containing only ertapenem or classical
ESBL-producing E.coli did not show any signs of sponta-
neous hydrolysis. Although a bit slow, the method thus
seems promising for the detection of the OXA 48-enzyme,
but has to be validated further with several more species
with varying OXA-enzymes.
The addition of inhibitors, as suggested by others [4,8]
in the assay might not be necessary as the time to detec-
tion was highly specific for the separation of KPC from
MBL-enzymes. However, we did not test isolates positive
for IMP-enzymes which might show rapid hydrolysis
and if in doubt, both APBA and DPA showed specific in-
hibition of KPC and MBL enzymes respectively and thus
served as further verification of the type of enzyme
expressed. In an attempt to streamline the two tests an
incubation time of 120 min was tested also for the KPC-
verification test. This was however not successful as the
high amount of APBA then needed (12 mg/mL) also
seemed to inhibit the action of NDM. No hydrolysis
could be observed in NDM incubated with high concen-
tration of APBA. The specificity of APBA is thus in this
assay dependent on the combination of incubation time
and concentration of APBA.
From a methodological point of view the assay was
easy to perform and interpret. We used a categorical in-
terpretation of the peaks as being present or not and did
not use the intensity ratio between the hydrolysis and
non-hydrolysis peaks previously proposed by Sparbier
[4]. Similar to Sparbier we observed the peak of 450 Da
which is a degradation peak of ertapenem. This peak was
by Sparbier observed only when performing a similar assay
directly from blood culture [4]. However, in this study the
450-peak was present in all runs but with a higher intensity
in the presence of KPC, VIM or NDM. The peak was not
included for the interpretation of hydrolysis. For further
studies this peak has to be characterized further.
Conclusions
This method allowed a rapid detection and verification
of KPC, NDM and VIM producing K. pneumoniae and
can be performed at a low cost. This study revealed some
caveats regarding the use of this type of hydrolysis assays
for the detection of carbapenemases as not all VIM-producing P. aeruginosa as well as none of the OXA-48
positive isolates were detected within the 120 min time
frame of the assay. Modifications of the assay and/or a
change of conditions and carbapenem used might over-
come this problem. If the rapid degradation of ertapenem
by KPC also with meropenem or imipenem as substrate
has to be investigated further and the definite sensitivity
and specificity of the assay have to be evaluated on a lar-
ger collection of isolates.
Methods
Hydrolysis assay
The hydrolysis assay was developed using a Microflex™
(Bruker Daltonics, Billerica, MA, USA) mass spectrometer.
The parameters settings were: ion source 1, 19.0 kV; ion
source 2, 17.2 kV; lens, 6.0 kV; detector gain, 2.5 kV. Spec-
tra were recorded in the mass range of 0–1000 Da with
60 Hz laser frequency. Each spectrum was obtained from
240 laser shots. The polished steel target plate (Bruker
Daltonics, Bremen, Germany) and HCCA matrix (2.5 mg
α-cyano-4-hydroxycinnamic acid dissolved in 50% acetoni-
tril, 47.5% HPLC-pure H2O and 2.5% trifluoroacetic acid,
(Bruker Daltonics)) was used. For calibration the Peptide
calibration standard II (Bruker Daltonics) was used. The
peaks employed for calibration were CCA [M+H]+ at
190.05 Da, CCA [2 M+H]+ at 379.09 Da and Bradykinin
(1–7) peak [M+H]+ at 757.40 Da.
The analysis of MALDI-TOF MS spectra was performed
with the Flexanalysis 3.3 software (Bruker Daltonics). The
spectra were smoothed and baseline subtracted and then
manually examined for the specific ertapenem related
peak patterns in the mass range of 4–600 Da previously
described [4]. To approve a spectrum as reliable at least
one sum buffer peak of hydrolysed or unhydrolysed erta-
penem had to have a minimum intensity of 104. The high
intensity proves the specificity of the peaks and guarantees
that no unspecific background noise is misinterpreted as a
significant peak.
Stability of ertapenem
Ertapenem for intravenous injection (Invanz®, MSD) was
used for the hydrolysis assay. 1.0 g of Invanz® was dis-
solved in 10 ml HPLC-pure water to a concentration of
100 mg/mL. Aliquots of 200 μL were stored at −20°C
or +4°C. The stability of ertapenem was tested after one
week and 6 months. The ertapenem (100 mg/mL) was
thawed and diluted in 10 mM ammonium hydrogen cit-
rate buffer pH 7.1 (ammonium citrate dibasic dissolved
in water, Sigma Aldrich) to the concentration 0.5 mg/mL.
2 μL were applied on a polished steel target plate and left
to dry and then overlaid with 1uL matrix. A mass spectrum
was obtained and a peak pattern consistent with unhydro-
lysed ertapenem, the presence of the 475.5 Da peak
of ertapenem, 498.5 Da [ertapenem+Na]+ and 520.5
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stability as previously described [4].
Detection of KPC-, VIM- and NDM-production
Based on the methods described by Sparbier and Hrabak
[4,5] an assay for the detection and verification KPC,
VIM and NDM production was developed using four
isolates of K. pneumoniae two isolates with KPC pro-
duction (CCUG 56233 and a clinical isolate) and two
VIM-producing clinical isolates. The assay was based
on ertapenem (0.5 mg/mL), a standardized inoculum of 4
McF, an optimal incubation time (15 min KPC and
120 min NDM and VIM) and the determination of the ap-
propriate amount of inhibitor for each incubation time.
Inhibitors used were 2,6-Pyridinedicarboxylic acid (DPA)
(Sigma Aldrich, Germany; 1.5 mg/mL, dissolved in water,)
and 3-aminophenylboronic acid (APBA) (Sigma-Aldrich,
Germany; 3.0 mg/mL, dissolved in water) and were freshly
prepared for each assay. Peaks generated were manually
examined and qualitatively judged by the presence of hy-
drolysed or unhydrolysed ertapenem respectively.
Test panel
Seventeen (17) clinical isolates of carbapenemase-
producing Klebsiella pneumoniae previously classified
as KPC- (n = 10, four KPC-2, two KPC-3 and four just
verified as KPC), VIM-1 (n = 3) or NDM-1-positive
(n = 4) using PCR (9–11) were tested. The carbapenem
susceptible K. pneumoniae ATCC 13882 and clinical
K. pneumoniae isolates phenotypically classified as having
a classical ESBL (n = 6) or with acquired AmpC, (n = 6)
were used as controls. Eleven (11) clinical isolates of car-
bapenem resistant Pseudomonas aeruginosa previously
classified as VIM-producing, two VIM-1, six VIM-2, two
VIM and one positive for IMP-14, with specific PCR
[15,16] were tested together with ten (10) carbapenem re-
sistant clinical isolates phenotypically verified as non-MBL
producers. A summary of the tested isolates are presented
in Table 1.
All isolates were retrieved on blood agar overnight at
35°C and verified to species using The Microflex™, and
the MALDI Biotyper 3.0 software (Bruker Daltonics) using
standard parameters. A score value of ≥ 2.0 was considered
a reliable species ID. Susceptibility testing was performed
for ertapenem, imipenem and meropenem using Etest
(BioMérieux, Marcy L´Etoille, France) on Mueller Hinton
agar according to the manufacturer’s instructions. Carba-
penemase production was verified using the KPC/MBL
Confirm ID Kit (Neo-Sensitabs™, Rosco diagnostica A/S)
K. pneumoniae and for P. aeruginosa.
The isolates were analyzed to test the method with the
same concentrations as described above. 1.5 mL of a
bacterial suspension (4 McF) in 0.9% NaCl was prepared
from overnight cultures and centrifuged at 13 400×gduring 2 minutes at room temperature. The supernatant
was removed by pipetting. The pellet was re-suspended
by pipetting in 20 μL of ertapenem (0.5 mg/mL) and in-
cubated for 15 min and 2 h respectively for the detection
of hydrolysis. For the verification of carbapenemase pro-
duction the bacterial pellet was re-suspended in 10 uL
ertapenem (1 mg/mL) together with 10 μL APBA (for
KPC) or 10 uL DPA (for VIM and NDM). The suspen-
sions were incubated in 35°C for 15 and 120 minutes
and then centrifuged at 13 400×g during 2 minutes at
room temperature. 2 μL of the supernatant was applied
to a polished steel target plate, left to dry, and 1 μL
matrix was applied on each spot before analysis with
MALDI-TOF MS. For each isolate tested ertapenem
alone was incubated 15 or 120 minutes as control of un-
specific hydrolysis.
Validation panel
As a validation set 22 isolates (Table 1) with varying re-
sistance phenotypes and mechanisms were blinded to
the primary investigator (ÅJ). The isolates were retrieved
on blood agar overnight at 35°C and verified to species
ID using The Microflex™, and the MALDI Biotyper 3.0
software (Bruker Daltonics) using standard parameters.
All isolates were incubated with ertapenem (0.5 mg/mL)
for 15 and 120 min and analyzed according to the final
protocol. Isolates positive at any time point were re-
incubated together with the inhibitor suitable for the
respective time point (i.e. APBA if hydrolysed within
15 min and DPA if hydrolysed within 2 h). Isolates negative
in the assay were incubated overnight, as well as ertapenem
only as negative control, and analysed after 24 h.
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